Tags : Prevention

Biotech COVID-19

Regeneron Initiates its First Clinical Study of Antibody Cocktail for

Shots: The company has reported the initiation of the first clinical trial of REGN-COV2. The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people that are at high risk of exposure and uninfected people with close exposure to a COVID-19 patient The first two adaptive […]Read More


Merck’s Ervebo Vaccine Receives the US FDA’s Approval for Prevention

Shots: The approval is based on the study conducted in Guinea during the 2014-2016 outbreak in individuals 18 years of age and older evaluated 3,537 contacts with laboratory-confirmed EVD who received either “immediate” or 21-day “delayed” vaccination with Ervebo The study showed that Ervebo was 100% effective in preventing Ebola cases with symptom onset >10 […]Read More


GSK Reports Results of M72/AS01E in P-IIb Study for the

Shots: The P-IIb study involves assessing of M72/AS01E vs PBO in 3,573 adults in a ratio (1:1) to prevent Mycobacterium tuberculosis infection from developing pulmonary tuberculosis disease in tuberculosis-endemic regions across 11 sites in Kenya, South Africa and Zambia The P-IIb study results demonstrated a reduction in the incidence of pulmonary TB in HIV-negative adults […]Read More